p27(kip1): A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers

American Journal of Pathology

Volumn 154, Issue 2, 1999, Pages 313-323

  Lloyd, Ricardo V ^a   Erickson, Lori A ^a   Jin, Long ^a   Kulig, Elzbieta ^a   Qian, Xiang ^a   Cheville, John C ^a   Scheithauer, Bernd W ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; PROTEIN P27; TRANSFORMING GROWTH FACTOR BETA; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; ENZYME INHIBITOR; MICROTUBULE ASSOCIATED PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; CANCER RESISTANCE; CARCINOGENESIS; CELL CYCLE; CELL DIFFERENTIATION; CELL HYPERPLASIA; CHROMOSOME 12P; CONTROLLED STUDY; HUMAN; INFLAMMATION; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; TUMOR SUPPRESSOR GENE; DRUG ANTAGONISM; FEMALE; GENE EXPRESSION; MALE; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASMS; PROGNOSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 0032587495     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65277-7     Document Type: Review

References (120)

1. Sherr CJ: G1 phase progression: cycling on cue. Cell 1994, 79:551-555
2. Hunter T, Pines J: Cyclins and cancer. II. Cyclin D and CDK inhibitors come of age. Cell 1994, 79:573-582
3. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995, 9:1149-1163
4. Kamb A: Cell-cycle regulators and cancer. Trends Genet 1995, 11:136-140
5. Massague J, Polyak K: Mammalian antiproliferative signals and their targets. Curr Opin Genet Dev 1995, 5:91-96
6. Clurman BE, Roberts JM: Cell cycle and cancer. J Natl Cancer Inst 1995, 87:1499-1501
7. Sherr CJ: Cancer cell cycles. Science 1996, 274:1672-1677
8. Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL, Matera AG, Xiong Y: Growth suppression by p18, a p16INK4/MTS1-and p14 INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994, 8:2939-2952
9. Hirai H, Roussel MF, Kato JY, Ashmun RA, Sherr CJ: Novel INK4 proteins. p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 1995, 15:2672-2681
10. ink4. Mol Cell Biol 1995, 15:2682-2688
11. Hirama T, Koeffler HP: Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995, 86:841-854
12. Jin X, Nguyen D, Zhang WW, Kyritsis AP, Roth JA: Cell cycle arrest and inhibition of tumor cell proliferation by the p16/INK4 gene mediated by an adenovirus vector. Cancer Res 1995, 55:3250-3253
13. Reed JA, Loganzo F Jr, Shea CR, Walker GJ, Flores JF, Glendening JM, Bogdany JK, Shiel MJ, Haluska FG, Fountain JW: Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995, 55:2713-2718
14. kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994, 78:59-66
15. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases Nature 1993, 366:701-704
16. Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity. is related to p21. Cell 1994, 78:67-74
17. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825
18. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A: p27 kip1, a cyclin-Cdk inhibitor links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 1994, 8:9-22
19. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ: p57/Kip2, a structurally distinct member of the p21/CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 1995, 9:650-662
20. Lee MH, Reynisdottir L, Massague J: Cloning of p57 Kip2. a cyclin-dependent kinase inhibitor witn unique domain structure and tissue distribution. Genes Dev 1995, 9:639-649
21. kip1 chromosomal mapping to 12p 12-12p 13.1 and absence of mutations in human tumors. Cancer Res 1995, 55:1211-1214
22. Kato JY, Matsuoka M, Polyak K, Massagué J, Sherr CJ: Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27kip1) of cyclin-dependent kinase 4 activation. Cell 1994, 79:487-496
23. Slingerland J, Hengst L, Pan C, Alexander D, Stampfer M, Reed S: A novel inhibitor of cyclin-Cdk activity detected in TGF-β-arrested epithelial cells. Mol Cell Biol 1994, 14:3683-3694
24. kip1 cyclin dependent-kinase inhibitor bound 10 the cyclin A-cdk 2 complex. Nature 1996, 382:325-331
25. Koff A, Ohtsuki ME, Polyak K, Roberts J, Massagué J: Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF β. Science 1993, 257:1689-1694
26. Firpo EJ, Koff A, Solomon MJ, Roberts JM: Inactivation of a Cdk2 inhibitor during interleukin-2 induced proliferation of human T lymphocytes. Mol Cell Biol 1994, 14:4889-4901
27. kip1 for restriction point control of the fibroblast cell cycle. Science 1996, 272:877-880
28. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE: Cyclin E-CDK2 is a regulator of p27kip1. Genes Dev 1997, 11:1464-1478
29. kip1 down regulation, passage through the restriction point and entry into S phase in growth factor-stimulated NIH 3T3 fibroblasts. Mol Cell Biol 1997, 17 5348-5358
30. kip1 in C3H 10 T1/2 mouse fibroblasts. Cancer Res 1995, 55:1413-1416
31. kip1 by the viral E1A oncoprotein in TGF-β treated cells. Nature 1996, 380:262-265
32. Qian X Jin L, Grande JP, Lloyd RV: Transforming growth factor-β and p27 expression in pituitary cells. Endocrinology 1996, 137:3051-3060
33. Morosetti R, Kawamata N, Gombart AF, Miller CW, Hatta Y, Hirama T, Said JW, Tomonaga M, Koeffler HP: Alterations of the p27/kip1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. Blood 1995, 86:1924-1930
34. Spirin KS, Simpson JF, Takeuchi S, Kawamata N, Miller CW, Koeffler HP: p27/kip1 mutation found in breast cancer. Cancer Res 1996, 56:2400-2404
35. kip1 on resistance of tumor cells to anti-cancer agents. Nature Med 1996, 2:1204-1210
36. kip1 gene and trisomy 12 in a subset of human pituitary adenomas. J Clin Endocrinol Metab 1997, 82:3141-3147
37. Katayose Y, Kim M, Rakkar ANS, Li Z, Cowan KH, Seth P: Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 1997, 57:5441-5445
38. k pl mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspace cascade. Mol Cell 1998, 1:553-563
39. kip1 is expressed transiently in developing myotomes and enhances myogenesis. Cell Growth Differ 1998, 9:1-11
40. Durand B, Gao FB, Raff M: Accumulation of the cyclin-dependent kinase inhibitor p27/kip1 and the timing of oligodendrocyte differentiation. EMBO J 1997, 16:306-317
41. kip1 in osteoblast-like cells during differentiation with parathyroid hormone Endocrinology 1997, 138:1995-2004
42. kip1. Mol Endocrinol 1998, 12:924-940
43. kip1 safeguards against inflammatory injury. Nature Med 1998, 4:575-580
44. kip1 display increased body size, multiple organ hyperplasia. retinal dysplasia, and pituitary tumors. Cell 1996, 85:707-720
45. Kiyokawa H, Kinerman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Mayday AC, Frohman LA, Koff A: Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27 kip1. Cell 1996, 85:721-732
46. kip1-deficient mice. Cell 1996, 85:733-744
47. kip1. J Clin Invest 1996, 97:1983-1988
48. St Croix B, Sheehan C, Rak JW, Florenes VA, Slingerland JM, Kerbel RS: E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27kip1. J Cell Biol 1998, 142: 557-571
49. Thomas GV, Szigeti K, Murphy M, Draetta G, Pagano M, Loda M: Down regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am J Pathol 1998, 153:681-687
50. Poon RY, Toyoshima H, Hunter T: Redistribution of the CDK inhibitor p27 between different cyclin-CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation. Mol Biol Cell 1995, 6:1197-1213
51. Nourse J, Firpo E, Flanagan UM, Coats S, Polyak K, Lee MH, Massague J, Crabtree GR, Roberts J: Interleukin-2-mediated elimination of p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994, 372:570-573
52. Watts CK, Brady A, Sarcevic B, deFazio A, Musgrove EA, Sutherland RL: Anti-estrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol 1995, 9:1804-1813
53. Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D, Lassar AB: Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 1995, 267:1018-1021
54. Pagano M, Tam SW, Theodoras AM, Romero-Beer P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995, 269:682-685
55. Morisaki H, Fujimoto A, Ando A, Nagata Y, Ikeda K, Nakanishi M. Cell cycle-dependent phosphorylation of p27 cyclin-dependent kinase (cdk) inhibitor of cyclin E Cdk2. Biochem Biophy Res Commun 1997, 240:386-390
56. kip1. EMBO J 1997, 16:5334-5344
57. kip1 accumulation during the cell cycle. Science 1996, 271:1861-1864
58. Alessandrini A, Chiaur DS, Pagano M: Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 1997, 11:342-345
59. Goldberg AL: Functions of the proteasome: the lysis at the end of the tunnel. Science 1995, 268:522-523
60. Rubin DM, Finley D: Proteolysis. The proteasome: a protein-degrading organelle? Cur Biol 1995, 5:854-858
61. Brandeis M, Hunt T: The proteolysis of mitotic cyclins in mammalian cells persists from the end of mitosis until the onset of S phase. EMBO J 1996, 15:5280-5289
62. kip1 activates CDC2. J Biol Chem 1997, 272:21669-21672
63. Millard SS, Yan JS, Nguyen H, Pagano M, Kiyokawa H, Koff A: Enhanced ribosomal association of p27Kip1 mRNA is a mechanism contributing to accumulation during growth arrest. J Biol Chem 1997, 272:7093-7098
64. Hochstrasser M: Ubiquitin, proteasomes. and the regulation of intracellular protein degradation Curr Opin Cell Biol 1995, 7:215-223
65. Feldman RMR, Correll CC, Kaplan KB, Deshaies RJ: A complex of Cdc4p, Skp1p and Cdc53p/Cullin catalyzes ubiquination of the phosphorylated CDK inhibitor Sic1p. Cell 1997, 91:221-230
66. kip1 expression in rodent pituitary cell lines. Am J Pathol 1998, 153:1475-1482
67. Steeg PS, Abram JS: Cancer prognostics: post, present and p27. Nature Med 1997, 3:152-154
68. kip1 protein: prognostic implications in primary breast cancer. Nature Med 1997, 3:227-230
69. kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med 1997, 3:222-225
70. 1a b) invasive breast carcinoma. Cancer Res 1997, 57:1259-1263
71. kip1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 1997, 94:6380-6385
72. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinoma. Nature Med 1997, 3:231-234
73. kip1 in multistage colorectal carcinogenesis. Cancer Res 1998, 58:114-122
74. Singh SP, Lipman J, Goldman H, Ellis FH Jr, Aizenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M, Loda M: Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 1998, 58:1730-1735
75. Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Susimachi K, Akiyoshi T: p27 expression and gastric carcinoma. Nature Med 1997, 3:593
76. Esposito V, Baldi A, DeLuca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997, 57:3381-3385
77. kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer. Am J Pathol 1998, 153:505-513
78. kip1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res 1998, 58:1042-1047
79. kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998, 58:542-548
80. Yang RM, Naitoh HJ, Murphy M, Wang H-J, Phillipson J, DeKernion JB, Loda M, Reiter RE: Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998, 159:941-945
81. kip1 in prostatic adenocarcinoma. Mod Pathol 1998, 11:324-328
82. Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, Gaudin PB, Fazzari M, Zhang Z-F, Massague J, Scher HI: Distinct altered patterns of p27Kip1 gene expression in benign prostatic hyperplasia and prostatic carcinoma, J Natl Cancer Inst 1998, 90:1284-1291
83. kip1 in malignant melanoma: inverse correlation with disease-free survival. Am J Pathol 1998, 153:305-312
84. kip1 in epithelial dysplasia and carcinoma of the oral cavity. Am J Pathol 1998, 152:585-590
85. kip1 expression in endocrine and other tumors. Am J Pathol 1997, 150:401-407
86. kip1 and Ki-67 in benign and malignant thyroid tumors. Mod Pathol 1998, 11:169-174
87. kip1 expression in papillary thyroid carcinomas. Endocr Pathol 1997, 4:293-300
88. kip1 protein. Am J Surg Pathol 1999 (in press)
89. kip1 expression in nontumorous and neoplastic human pituitaries. Am J Pathol 1997, 151:509-519
90. kip1 gene in corticotropin-secreting tumors. Oncogene 1998, 16:69-76
91. Minna JB, Nau MM, Chioa I, Ihde DC: Lung cancer. Principles and Practice of Oncology. Edited by Denita VT, Rosenberg S, Hellmen S, Philadelphia, JB Lippincott, 1989, pp 591-705
92. kip1 is abrogated by c-Myc. EMBO J 1996, 15:6595-6604
93. kip1 expression is inversely proportional to the proliferative index. Am J Pathol 1997, 151:151-160
94. kip1, a cyclin-dependent kinase inhibitor. Am J Pathol 1998, 153:175-182
95. Kovacs K, Asa SL: Functional endocrine pathology. Malden, MA, Blackwell Science, 1998
96. Shirman I, Melmed S: Genetic basis of endocrine disease: pituitary tumor pathogenesis. J Clin Endocrinol Metab 1997, 82:1675-1681
97. Prezant TR, Levine J, Melmed S: Molecular characterization of the MEN I tumor suppressor gene in sporadic pituitary tumors. J Clin Endocrinol Metab 1998, 83:1388-1391
98. Clayton RN, Bogglid M, Bates AS, Bicknell J, Simpson D, Farreli W: Tumor suppressor genes in the pathogenesis of human pituitary tumors. Horm Res 1997, 47:185-193
99. Arnold A: Genetic basis of endocrine diseases: molecular genetics of parathyroid gland neoplasia. J Clin Endocrinol Metab 1993, 77: 1108-1112
100. Arnold A: Molecular mechanisms of parathyroid neoplasia. Endocrinol Metab Clin North Am 1994, 23:93-107
101. Farid NR, Shi Y, Zou M: Molecular basics of thyroid cancer. Endocr Rev 1994, 15:202-232
102. Gicquel C, Bertagna X, LeBouc Y: Recent advances in the pathogenesis of adrenocortical tumors. Eur J Endocrinol 1995, 133:133-144
103. kip2 indicate a role in Beckwith-Wiedemann syndrome. Nature 1997, 387:151-158
104. kip2, insulin-like growth factor II, and H19, in adrenal tumors and cultured adrenal cells. J Clin Endocrinol Metab 1997, 82:1766-1771
105. INK4a gene product in human pituitary tumors. Cancer Res 1996, 56:2493-2496
106. Woloschak M, Yu A, Post KD: Frequent inactivation of the p16 gene in human pituitary tumors by gene methylation. Mol Carcinog 1997, 19:221-224
107. Arnold A, Kim HG, Gaz RD, Eddy RL, Fukushima Y, Byers MG, Shows TB, Kronenberg HM: Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest 1989, 83:2034-2040
108. Qian X, Kulig E, Jin L, Lloyd RV: Expression of D-type cyclins in normal and neoplastic rat pituitary. Endocrinology 1998, 139:2058-2067
109. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP: Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998, 72:141-196
110. Fagin JA: Genetic basis of endocrine disease. III. Molecular defects in thyroid gland neoplasia. J Clin Endocrinol Metab 1992, 75:1398-1400
111. Namba H, Hara T, Tukazaki T, Migita K, Ishikama N, Iro K, Nagataki S, Yamashita S: Radiation-induced G1 arrest is selectively mediated by the p53-WAF/Cip1 pathway in human thyroid cells. Cancer Res 1995, 55:2075-2080
112. Zedenius J, Larsson C, Wallin G, Bäckdahl M, Aspenblad U, Höög A, Børresen A-L, Auer G. Alterations of p53 and expression of WAF1/p21 in human thyroid turners. Thyroid 1996, 6:1-9
113. kip1 expression. Mol Cell Biol 1998, 18:1996-2003
114. kip1 regulated by mitogen-activated protein kinase (MEK1). Proc Natl Acad Sci USA 1998, 95:1091-1096
115. Pedrem A, Razandi M, Hu R-M, Levin ER: Astrocyte progression from G1 to S phase of the cell cycle depends upon multiple protein interaction. J Biol Chem 1998, 273:13966-13972
116. Sgambato A, Zhang YJ, Arber N, Hibsoosh N, Doki Y, Ciaparrone M, Santella RM, Cittadini A, Weinstein IB: Deregulated expression of p27Kip1 in human breast cancers. Clin Cancer Res 1997, 3:1879-1887
117. Dgambato A, Zhang YJ, Ciaparrone M, Son JW, Cittadini A, Santella RM, Weinstein IB: Overexpression of p27Kip1 inhibits the growth of both rormal and transformed human mammary epithelial cells. Cancer Res 1998, 58:3448-3454
118. Jacks T, Weinberg RA: The expanding role of cell cycle regulators. Science 1998, 280:1035-1036
119. kip1 mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 1998, 12:2899-2911
120. Kip1 is haplo-insufficient for tumour suppression. Nature 1998, 396:177-180